MARKET

BDSI

BDSI

BDSI
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.180
-0.040
-1.24%
Closed 19:48 05/13 EDT
OPEN
3.280
PREV CLOSE
3.220
HIGH
3.280
LOW
3.100
VOLUME
741.68K
TURNOVER
--
52 WEEK HIGH
5.45
52 WEEK LOW
3.040
MARKET CAP
313.40M
P/E (TTM)
12.95
1D
5D
1M
3M
1Y
5Y
Insider Trends: Insider Purchase Adds to BioDelivery Sciences International Positive Trend
MT Newswires · 14h ago
Opioid Use Disorder Market Size 2021 | Is Projected to grow USD 4.81 billion in 2028 at a CAGR of 8.7%
Pune, India, May 12, 2021 (GLOBE NEWSWIRE via COMTEX) -- Pune, India, May 12, 2021 (GLOBE NEWSWIRE) -- Opioid Use Disorder Market Size| 2021 Covid-19 Impact...
GlobeNewswire · 1d ago
H.C. Wainwright Thinks BioDelivery’s Stock is Going to Recover
In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on BioDelivery (BDSI), with a price target of $5.50. The company's
SmarterAnalyst · 3d ago
Diabetic Neuropathic Pain Drug Market Size, Market Share, Application, Analysis, Regional Outlook, Growth, Trends and Forecasts 2021 - 2028 By Ameco Research
Comserve · 4d ago
BioDelivery Sciences International (BDSI) Misses Q1 Earnings Estimates
BioDelivery (BDSI) delivered earnings and revenue surprises of -28.57% and 0.07%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 14:20
BioDelivery Sciences Reports First Quarter 2021 Results
Total Company Net Revenue of $41 Million, an Increase of 7% versus Prior Year
GlobeNewswire · 05/06 12:53
BioDelivery Sciences Intl Q1 EPS $0.05 Misses $0.07 Estimate, Sales $41.00M Miss $41.34M Estimate
BioDelivery Sciences Intl (NASDAQ:BDSI) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.07 by 28.57 percent. This is unchanged from the same period last year. The company
Benzinga · 05/06 12:49
BRIEF-BioDelivery Sciences Reports Q1 EPS Of $0.05
reuters.com · 05/06 12:37
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BDSI. Analyze the recent business situations of BDSI through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BDSI stock price target is 6.96 with a high estimate of 8.00 and a low estimate of 5.50.
EPS
Institutional Holdings
Institutions: 221
Institutional Holdings: 79.65M
% Owned: 80.82%
Shares Outstanding: 98.55M
TypeInstitutionsShares
Increased
55
8.97M
New
21
2.52M
Decreased
41
4.81M
Sold Out
21
6.57M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.01%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
Peter Greenleaf
Chairman/Director
Francis O'Donnell
President
Scott Plesha
Chief Executive Officer
Jeffrey Bailey
Chief Financial Officer
Terry Coelho
Vice Chairman/Director
Mark Sirgo
Chief Financial Officer/Treasurer
Mary Coelho
Senior Vice President
Joseph Lockhart
Senior Vice President
Kevin Ostrander
Chief Compliance Officer/General Counsel/Secretary
James Vollins
Other
Thomas Smith
Independent Director
Todd Davis
Independent Director
Kevin Kotler
Independent Director
Vanila Singh
Director
W. Mark Watson
Independent Director
William Watson
No Data
  • All
  • Financials
  • Insiders
More
About BDSI
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Webull offers kinds of BioDelivery Sciences International, Inc. stock information, including NASDAQ:BDSI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BDSI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BDSI stock methods without spending real money on the virtual paper trading platform.